Semaglutide 2mg - reagent in vial

Semaglutide 2mg is a synthetic peptide designed to interact with key metabolic pathways associated with glucose regulation and energy homeostasis under laboratory conditions. Consisting of 31 amino acids, the semaglutide contains strategic structural modifications, such as the replacement of alanine with α-aminoisobutyric acid (Aib) at position 8, which increases its enzymatic stability by resisting degradation by dipeptidylpeptidase-4 (DPP-4). In addition, acylation with the hexadecanedioic acid moiety enables strong binding to albumin, extending the half-life in circulation and bioavailability.

Under controlled laboratory conditions, Semaglutide interacts with specific receptors associated with metabolic regulation, affecting processes such as energy expenditure and lipid metabolism in non-human research models. Studies in non-human models indicate its role in modulating nutrient utilisation and metabolic signalling, making it a valuable research tool.

The stability and receptor specificity of Semglutide place it as a key peptide for studying the complex physiological mechanisms regulating energy balance and glucose homeostasis, providing important information on metabolic function in non-human research models.

See also BAM15 reagent 60 capsules/25mcg 

Mechanism of action of semaglutide 2mg in research terms

Available literature and results research Preclinical and experimental studies indicate that semaglutide is under intensive investigation for its effects on glucose regulation and energy balance. The observed effects are due to its selective action on GLP-1 receptors, which play an important role in metabolic signalling.

Studies suggest that activation of GLP-1 receptors in pancreatic β-cells is associated with an increase in glucose-dependent insulin secretion, particularly under postprandial conditions. This mechanism is being investigated as one of the key components of glucose control in research models.

In parallel, studies have observed inhibition of glucagon secretion by pancreatic α-cells, which may lead to a reduction in endogenous hepatic glucose production. This phenomenon is an important area of interest in the context of research on hormonal and metabolic balance.

Experimental data also indicate that semaglutide affects gastrointestinal motility, including slowing gastric emptying. This effect is being analysed for its potential relevance to the regulation of the feeling of satiety and the control of energy intake under laboratory conditions.

In addition, central nervous system studies have shown that semaglutide affects brain structures involved in the regulation of appetite and hunger signals. This mechanism remains the subject of further experimental studies, particularly in the context of neuroendocrine control of body weight and metabolic adaptation.

Source: Semaglutide for Weight Management: A Clinical ReviewThe product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.